Frishman W H, Eisen G, Lapsker J
Albert Einstein College of Medicine, Bronx, New York.
Med Clin North Am. 1988 Mar;72(2):441-8. doi: 10.1016/s0025-7125(16)30778-7.
Terazosin is a new long-acting, selective alpha 1-adrenergic antagonist. Its pharmacokinetic and pharmacodynamic profiles are similar to those of prazosin, but terazosin has a half-life three to four times longer. This allows once daily dosing of terazosin and a potential advantage in ensuring patient compliance to treatment. Terazosin has been evaluated alone and in combination with other drugs for the treatment of mild to moderate hypertension. Terazosin has been shown to have favorable lipid and side effect profiles. Unlike prazosin, the drug is available (but not yet marketed) in parenteral form. Its gradual onset of action with intravenous use would limit its potential application in hypertensive emergencies. Other possible uses for terazosin might include treatment of congestive heart failure and Raynaud's phenomenon, but definitive studies are needed.
特拉唑嗪是一种新型长效、选择性α1肾上腺素能拮抗剂。其药代动力学和药效学特征与哌唑嗪相似，但特拉唑嗪的半衰期长三至四倍。这使得特拉唑嗪可以每日给药一次，在确保患者治疗依从性方面具有潜在优势。特拉唑嗪已单独及与其他药物联合用于治疗轻至中度高血压。已证明特拉唑嗪具有良好的血脂和副作用特征。与哌唑嗪不同，该药物有肠胃外剂型（但尚未上市）。静脉使用时其作用起效缓慢，这将限制其在高血压急症中的潜在应用。特拉唑嗪的其他可能用途可能包括治疗充血性心力衰竭和雷诺现象，但需要进行确定性研究。
